Structured evidence table for Berberine Cholesterol Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Cholesterol Meta-Analysis | As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Cholesterol Meta-Analysis | Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Cholesterol Meta-Analysis | Despite of the benefits on lipid profile and glucose metabolism, the effect of berberine on the risk of IHD and diabetes has not been clarified. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Cholesterol Meta-Analysis | 1 2 3 4 Ischemic heart disease (IHD) is the single leading cause of mortality and poses a heavy burden on healthcare, which accounts for ~16% of all deaths globally. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Cholesterol Meta-Analysis | The primary prevention of CVD through the management of dyslipidemia, a major risk factor for CVD, is a critical strategy for improving population health outcomes and reducing the associated economic impact. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Cholesterol Meta-Analysis | Statin use has increased substantially in recent years, with nearly two-thirds of those taking statins for primary prevention. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Cholesterol Meta-Analysis | The clinical guidelines also recommend statin use among people previously considered at low risk of CVD. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
| Berberine Cholesterol Meta-Analysis | 1 2 4 – 5 6 , 7 4 8 10 ,– 11 12 13 16 – Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, which poses a heavy burden on healthcare. | 4 | Xia Yuanqing (2026) | Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland |
Source documents